The BREAST-i™ device has a number of benefits for the user:
- Easy to use, without the need for lubrication or breast compression
- Assists in keeping an eye on your breasts, at your convenience
- Utilises patented technology (European Patent No. EP1750575B)
- Advanced skin sensors for safety with four light intensity settings
- UK manufactured to quality standards ISO 13485:2016
- CE Marked and MHRA Registration
Screening with the BREAST-i™
A powerful tool in giving an early edge in the ability to monitor blood vessels, identify abnormal tissue and spot potential tumours/lesions. Some small cancers may grow to become life threatening, others may remain dormant or even disappear.
Any cancer detected by BREAST-i™ is likely to be serious since it is detected by associated angiogenesis, implying that it is already in the exponentially growing phase. It must be realised that X-rays and light are monitoring different features of the breast, tissue density and neovascularisation, respectively. Should a shadow or cluster be spotted then medical consultation should always be pursued.
Light from the bright bulbs is scattered through the breast tissues. Helping users to identify any issues.
Use the device whilst sitting or standing, looking down directly at your breasts. You can also use a mirror to help.
You can also visit a GP’s office, here the BREAST-i examination can be carried out by either a doctor or surgeon.
Place the device under your breast. Note the appearance, here there are no obvious shadows seen.
Keep an eye out for any dark areas which weren’t there previously. If present, seek medical advise from a GP.
You may see enlarged blood vessels and/or small, feint shadow around the vessels. Again, see a doctor.
Lit with the BREAST-i this image displays a normal breast with veins, appearing mainly bright throughout.
Breast with visible mass. The dark area is caused by angiogenesis, and the blood vessels feeding it are obvious.
||5°C to 40°C, 20% to 80% R.H.
||-40°C to +70°C
||Complied with EN60601-1:2006 + A1:2013
||Complied with EN61326-1:2013
||50 x 55 x 175mm (WxHxL)
|The full product brochure is available to download here:
BREAST-i Leaflet (1.9mb)
Relevant research papers:
Nigel Bundred et al. ‘Preliminary results using computerised tele-diaphanography for the investigation of breast disease.’ 1986. British Journal of Hospital Medicine. (Report documenting initial results of using a tele-diaphanography device to investigate breast disease)
David Watmough. ‘Diaphanography; Mechanism responsible for the images.’ 1982. Acta Radiologica. Oncology. (Showing absorption of light by red blood cells and presence of new vessels around cancer, cause observable shadows when breast is illuminated)
Max Cutler. ‘Transillumination as an aid in the diagnosis of breast lesions.’ 1929. Surgery Gynecol Obstet. (American Surgeon M. Cutler first demonstrated the use of light to examine the female breast)
David Watmough. ‘Son et Lumiere; a combined Optical Doppler ultrasound approach to detection of breast cancer.’ 1989. Rad Magazine. (Proposing an optical doppler method to supplement mammography)
Frank Ghartey et al. ‘BREAST-i is an effective and reliable adjunct screening tool for detecting early tumour related angiogenesis of breast cancers in low resource sub-Saharan countries.’ 2018. International Journal of Breast Cancer. (Testing of over 1000 Ghanaian woman reports a sensitivity for breast cancer of 94% using the BREAST-i™)
Nargis Labib et al. ‘Evaluation of BreastLight as a tool for early detection of breast lesions among females attending National Cancer Institute, Cairo University.’ 2013. Asian Pacific Journal of Cancer Prevention. (In an investigation using Breastlight [a precursor to the BREAST-i] found a sensitivity for cancer of 93%)